PE20181331A1 - NUEVOS DERIVADOS DE IMIDAZO [4,5-b] PIRIDINA UN PROCESO PARA SU PREPRACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN - Google Patents
NUEVOS DERIVADOS DE IMIDAZO [4,5-b] PIRIDINA UN PROCESO PARA SU PREPRACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENENInfo
- Publication number
- PE20181331A1 PE20181331A1 PE2018000443A PE2018000443A PE20181331A1 PE 20181331 A1 PE20181331 A1 PE 20181331A1 PE 2018000443 A PE2018000443 A PE 2018000443A PE 2018000443 A PE2018000443 A PE 2018000443A PE 20181331 A1 PE20181331 A1 PE 20181331A1
- Authority
- PE
- Peru
- Prior art keywords
- imidazo
- pyridine
- pharmaceutical compositions
- prepration
- hydrogen
- Prior art date
Links
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- GMSJISXIJQFJEV-UHFFFAOYSA-N 4-[2-methyl-3-(3-phenylcyclobutyl)imidazo[4,5-b]pyridin-5-yl]pyridine-2,6-diamine Chemical compound CC1=NC=2C(=NC(=CC=2)C2=CC(=NC(=C2)N)N)N1C1CC(C1)C1=CC=CC=C1 GMSJISXIJQFJEV-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 abstract 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 abstract 1
- 101000749294 Homo sapiens Dual specificity protein kinase CLK1 Proteins 0.000 abstract 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Se refiere a compuestos de formula (I), sus enantiomeros, diasteroisomeros y sus sales de adicion de los mismos farmaceuticamente aceptable; en la que R1 es un grupo ciano, un atomo de halogeno, un grupo alquilo(C1-C6), entre otros; R2 es hidrogeno, grupo alquilo(C1-C6) lineal o ramificado, entre otros; R3 es un atomo de hidrogeno, halogeno, entre otros; R4 y R5 cada uno independientemente de los otros, representan un atomo de hidrogeno o halogeno; estos compuestos son derivados de imidazo [4,5-b] piridina y son inhibidores de DYRK1/CLK1. Es compuesto preferido: 4-[2-metil-3-(3-fenilciclobutil)-3H-imidazo[4,5-b]piridin-5-il]piridina-2,6-diamina, entre otros. Tambien se refiere a procesos para su preparacion, composiciones farmaceuticas y usos de estas, en el tratamiento del cancer, trastornos neurodegenerativos o trastornos metabolicos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1559252A FR3041639B1 (fr) | 2015-09-30 | 2015-09-30 | NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181331A1 true PE20181331A1 (es) | 2018-08-20 |
Family
ID=54979755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000443A PE20181331A1 (es) | 2015-09-30 | 2016-09-30 | NUEVOS DERIVADOS DE IMIDAZO [4,5-b] PIRIDINA UN PROCESO PARA SU PREPRACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20180273528A1 (es) |
| EP (1) | EP3356363A1 (es) |
| JP (1) | JP2018535931A (es) |
| KR (1) | KR20180054858A (es) |
| CN (1) | CN108137581A (es) |
| AU (1) | AU2016333505A1 (es) |
| BR (1) | BR112018006157A2 (es) |
| CA (1) | CA2999935A1 (es) |
| CL (1) | CL2018000783A1 (es) |
| CO (1) | CO2018003473A2 (es) |
| CR (1) | CR20180181A (es) |
| CU (1) | CU20180028A7 (es) |
| DO (1) | DOP2018000083A (es) |
| EA (1) | EA201890821A1 (es) |
| EC (1) | ECSP18023253A (es) |
| FR (1) | FR3041639B1 (es) |
| HK (1) | HK1255804A1 (es) |
| IL (1) | IL258341A (es) |
| MA (1) | MA43020A (es) |
| MX (1) | MX2018003860A (es) |
| NI (1) | NI201800043A (es) |
| PE (1) | PE20181331A1 (es) |
| PH (1) | PH12018500650A1 (es) |
| SV (1) | SV2018005657A (es) |
| TN (1) | TN2018000090A1 (es) |
| WO (1) | WO2017055530A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12528810B2 (en) | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| CN108822103A (zh) * | 2018-07-28 | 2018-11-16 | 刘凤娟 | 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用 |
| EP3856186A4 (en) * | 2018-09-28 | 2022-07-06 | Arizona Board of Regents on behalf of the University of Arizona | SMALL MOLECULE DYRK1/CLK INHIBITORS AND THEIR USES |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| CR20210215A (es) | 2018-10-31 | 2021-06-17 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CA3153531A1 (en) * | 2019-09-11 | 2021-03-18 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015012432A (es) * | 2013-03-13 | 2016-02-05 | Abbvie Inc | Inhibidores piridinicos de la cinasa cdk9. |
-
2015
- 2015-09-30 FR FR1559252A patent/FR3041639B1/fr not_active Expired - Fee Related
-
2016
- 2016-09-30 AU AU2016333505A patent/AU2016333505A1/en not_active Abandoned
- 2016-09-30 EA EA201890821A patent/EA201890821A1/ru unknown
- 2016-09-30 CU CUP2018000028A patent/CU20180028A7/es unknown
- 2016-09-30 BR BR112018006157A patent/BR112018006157A2/pt not_active Application Discontinuation
- 2016-09-30 EP EP16774682.5A patent/EP3356363A1/en not_active Withdrawn
- 2016-09-30 US US15/763,248 patent/US20180273528A1/en not_active Abandoned
- 2016-09-30 HK HK18114643.2A patent/HK1255804A1/zh unknown
- 2016-09-30 JP JP2018516194A patent/JP2018535931A/ja active Pending
- 2016-09-30 MA MA043020A patent/MA43020A/fr unknown
- 2016-09-30 KR KR1020187012175A patent/KR20180054858A/ko not_active Withdrawn
- 2016-09-30 CA CA2999935A patent/CA2999935A1/en not_active Abandoned
- 2016-09-30 MX MX2018003860A patent/MX2018003860A/es unknown
- 2016-09-30 PE PE2018000443A patent/PE20181331A1/es unknown
- 2016-09-30 CR CR20180181A patent/CR20180181A/es unknown
- 2016-09-30 WO PCT/EP2016/073395 patent/WO2017055530A1/en not_active Ceased
- 2016-09-30 CN CN201680058054.0A patent/CN108137581A/zh not_active Withdrawn
- 2016-09-30 TN TNP/2018/000090A patent/TN2018000090A1/en unknown
-
2018
- 2018-03-22 SV SV2018005657A patent/SV2018005657A/es unknown
- 2018-03-23 PH PH12018500650A patent/PH12018500650A1/en unknown
- 2018-03-23 NI NI201800043A patent/NI201800043A/es unknown
- 2018-03-25 IL IL258341A patent/IL258341A/en unknown
- 2018-03-26 EC ECIEPI201823253A patent/ECSP18023253A/es unknown
- 2018-03-26 CL CL2018000783A patent/CL2018000783A1/es unknown
- 2018-03-27 DO DO2018000083A patent/DOP2018000083A/es unknown
- 2018-03-28 CO CONC2018/0003473A patent/CO2018003473A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2018000083A (es) | 2018-10-15 |
| IL258341A (en) | 2018-05-31 |
| CO2018003473A2 (es) | 2018-07-10 |
| SV2018005657A (es) | 2018-07-31 |
| CA2999935A1 (en) | 2017-04-06 |
| HK1255804A1 (zh) | 2019-08-23 |
| FR3041639A1 (es) | 2017-03-31 |
| MX2018003860A (es) | 2018-08-16 |
| MA43020A (fr) | 2018-08-08 |
| US20180273528A1 (en) | 2018-09-27 |
| CL2018000783A1 (es) | 2018-09-21 |
| CR20180181A (es) | 2018-06-22 |
| EP3356363A1 (en) | 2018-08-08 |
| AU2016333505A1 (en) | 2018-04-19 |
| KR20180054858A (ko) | 2018-05-24 |
| WO2017055530A1 (en) | 2017-04-06 |
| FR3041639B1 (fr) | 2019-01-25 |
| CN108137581A (zh) | 2018-06-08 |
| JP2018535931A (ja) | 2018-12-06 |
| CU20180028A7 (es) | 2018-07-05 |
| ECSP18023253A (es) | 2018-04-30 |
| EA201890821A1 (ru) | 2018-10-31 |
| NI201800043A (es) | 2018-06-21 |
| PH12018500650A1 (en) | 2018-10-01 |
| TN2018000090A1 (en) | 2019-07-08 |
| BR112018006157A2 (pt) | 2018-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181331A1 (es) | NUEVOS DERIVADOS DE IMIDAZO [4,5-b] PIRIDINA UN PROCESO PARA SU PREPRACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| AR067886A1 (es) | Derivados de acido azabifenilaminobenzoico | |
| AR078786A1 (es) | Derivados de la cromenona | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| PE20190337A1 (es) | NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| PE20200700A1 (es) | Compuestos macrociclicos y usos de los mismos | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| PE20181024A1 (es) | Derivados de ciclohexano sustituido con amido | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| PE20190437A1 (es) | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo | |
| MX2015009950A (es) | Compuestos de imidazopiridina y sus usos. | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| AR085987A1 (es) | Compuestos tri- y tetraciclicos pirazol[3,4-b]piridina como agentes antineoplasicos | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| AR107030A1 (es) | Inhibidores aza-bencimidazol de pad4 | |
| AR070188A1 (es) | Derivados de sulfonamidas sustituidas | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| AR109651A1 (es) | Compuestos de piridina y pirazina como inhibidores de ripk2 |